liver tissue occurs not only in hepatic cirrhosis but also in 1. The zinc status and drug-metabolizing ability of 15 patients with histologically diagnosed hepatic cirrhosis were studied. Zinc status was assessed using both serum and leucocyte zinc concentrations, and drug-metabolizing ability was assessed by antipyrine kinetics.
INTRODUCTION
Zinc-deprived animals have delayed elimination of some drugs [l] , raising the possibility that zinc is required for the normal activity of drug-metabolizing enzyme systems.
Intracellular zinc depletion occurs in patients with hepatic cirrhosis. This is probably caused by a combination of decreased dietary intake, malabsorption and increased loss via the gastrointestinal tract and in the urine [2, 3] . A recent study suggests that zinc deficiency in Correspondence: Dr Michael Barry, Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland. less advanced alcoholic &d non-alcoholic liver disease such as chronic active hepatitis [4] .
Three major factors determine the rate of drug elimination by the liver: delivery by liver blood flow, binding of the compound to plasma proteins and, most importantly, the activity of hepatic drug metabolism enzymes [5-81. The hepatic cytochrome P-450-dependent microsomal mono-oxygenases are responsible for the biotransformation of a wide variety of drugs. The activities of these enzymes have been shown to be impaired in liver tissue from patients with alcoholic cirrhosis [9] . In this study, we investigate the possibility that intracellular zinc deficiency in patients with hepatic cirrhosis may influence hepatic microsomal enzyme activity and hence delay drug elimination.
The assessment of zinc status is difficult as zinc is predominantly an intracellular ion. We therefore measured both serum and leucocyte zinc concentrations as the latter has been shown to represent most closely the main intracellular sites if zinc storage [ 101. Antipyrine was chosen as the marker of hepatic oxidative drug-metabolizing ability because of its well recognized properties which include almost complete hepatic metabolism with a low hepatic extraction ratio' independent of liver blood flow, negligible renal elimination and insignificant plasma protein binding [ll, 121.
METHODS
Fifteen patients (10 male, mean age 52 years) took part in the study which was approved by the hospital Ethics Committee. All patients had histologically diagnosed hepatic cirrhosis; in 11 patients liver disease was secondary to chronic alcohol intake, two patients had chronic active hepatitis, one patient had haemochromatosis and one had primary biliary cirrhosis. All patients were in a clinically stable condition without associated cardiac or renal pathology; none was on concomitant medication known to interfere with drug metabolism (two were on diuretics, one was on prednisolone 5 mg daily). All patients were hospitalized at the time of study and did not ingest alcohol for at least 7 days before the study. The severity of liver disease was assessed by using the Child Turcotte classification, where a combination of clinical features, e.g. nutritional status, encephalopathy, ascites and laboratory measurements (plasma albumin and bilirubin), are used [5] .
Zinc levels were measured in both serum and leucocytes by atomic absorption spectrophotometry. At 08.00 hours, a fasting blood sample (50 ml) was taken with minimal stasis into trace-element-free vacutainers containing preservative-free sodium heparin (50 i.u./ml). Erythrocytes prepared from an aliquot of whole blood were washed in saline (1 50 mmol/l NaCI). Centrifugation at 800 g resulted in sedimentation of the cells. Dextran sedimentation (dextran/blood ratio, 1 :4) yielded mixed leucocytes. The mixed leucocyte population was separated into mononuclear and polymorphonuclear fractions by centrifugation on Ficoll-Paque. The remaining erythrocytes were eliminated by hypotonic lysis. Cells were counted under ultraviolet light using a fluorescent dye (ethidium bromide 16 mg/l and Acridine Orange 4 mg/l). The purity and viability of the preparations were checked. The leucocytes were centrifuged to sediment the cells. Cell pellets in pre-weighed glass tubes were dried at 100 "C for 16 h and then weighed to the nearest 0.05 mg within 2 h of removal from the oven. The dried pellets were extracted with 0.3 ml of mol/l HCl for 20 h before analysis for trace elements by atomic absorption spectrophotometry. Care was taken throughout to avoid contamination. The zinc status of the cirrhotic patients was compared with that of 15 healthy age-and sex-matched control subjects.
Antipyrine clearance, an index of oxidative drug metabolism, was determined from the systemic clearance of a single intravenous dose of antipyrine (10 mg/kg). Blood samples were taken from an indwelling cannula at 0, 3, 6, 9, 12 and 24 h, and antipyrine concentrations were determined by high-pressure liquid chromatography. Antipyrine clearance was calculated from the intravenous dose (D) and the area under the plasma concentration versus time curve (AUC; calculated by the trapezoidal rule), according to the equation:
Statistical analysis was performed using non-parametric tests. The Wilcoxon rank sum test on unpaired data (the two-sample test) was used as a test of significance of difference between mean values. Correlation coefficients were calculated by least square linear regression analysis.
RESULTS
Both serum and leucocyte zinc levels were found to be significantly ( P < 0.05) reduced in patients with hepatic cirrhosis compared with the control group ( Table 1 ). The mean ( ~S E M ) antipyrine clearance of the chronic liver disease patients was 31.2 f 3.6 ml/min. A significant positive correlation was noted between leucocyte zinc levels and antipyrine clearance in the patients with hepatic cirrhosis (Fig. 1 ). No such relationship was noted with antipyrine half-life and no significant correlation between serum zinc concentrations and antipyrine clearance was found. Leucocyte zinc concentrations and antipyrine clearance were not influenced by the severity of liver dysfunction (Fig. 2) .
DISCUSSION
Zinc is an essential trace element in man and its deficiency is a recognized feature of chronic liver disease. Zinc is an essential component of over 200 metalloenzymes and thus plays a significant role in many enzymatic processes [ 131. Experimental animal data suggest that zinc is essential for the normal activities of some drug-metabolizing enzyme systems. Studies of microsomal enzyme activities in zinc-depleted rats demonstrate a reduction in the rate of metabolism of a number of drugs including aminopyrine and p-nitrobenzoic acid [l] . A prolongation of the activities in vivo of certain drugs, e.g. barbiturates, is also seen in these zincdeficient rats. Correction of the zinc deficiency state restored normal rates of drug metabolism, suggesting a possible role for zinc in drug metabolism [l] . A previous study in patients with hepatitis (alcoholic) and hepatic cirrhosis suggested a significant relationship between zinc status, represented by serum zinc, and antipyrine elimination half-life [ 141. Unfortunately, no measure of antipyrine clearance was made in that study and the possibility of disease-related alterations in the volume of distribution of antipyrine was not considered. Furthermore, it must be recognized that zinc is found predominantly intracellularly (99%) and therefore a more accurate assessment of zinc status would be obtained from measurement of tissue zinc levels. Leucocytes provide an easily accessible tissue for the determination of zinc status. Leucocyte zinc has been shown to accurately reflect the main intracellular sites of zinc storage, e.g. muscle tissue zinc, both in chronic liver disease patients and in normal control subjects [lo] . Leucocyte zinc also fluctuates less than serum zinc levels in response to a wide range of conditions, including stress, acute and chronic infections and alcohol intake [lo] .
Our results show no significant relationship between serum zinc levels and antipyrine clearance. The variability of serum zinc levels may also contribute to this finding. The relationship between leucocyte zinc levels and antipyrine clearance was, however, significant. We found that the lower the zinc status, the greater the impairment in antipyrine clearance (Fig. 1) . This supports the findings of experimental animal studies which have suggested a facilitatory role for zinc in drug metabolism. Despite the fact that these two variables are correlated, it is possible that both zinc status and antipyrine clearance are independent markers for liver disease.
In this study leucocyte zinc concentration and antipyrine clearance were not influenced by the severity of liver disease, as assessed by using the Child Turcotte classification. This is consistent with a previous study in which antipyrine elimination could not easily distinguish between patients with and without the various complications of cirrhosis [15] . Furthermore, associations are not necesssarily causally related. The effect of zinc supplementation on impaired drug metabolism in cirrhosis requires study.
